CD79B is altered in 15.25% of diffuse large B-cell lymphoma patients [3].

CD79B is an inclusion criterion in 1 clinical trial for diffuse large B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains CD79B status and diffuse large B-cell lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

CD79B is altered in 1.08% of mycosis fungoides patients [3].

CD79B is an inclusion criterion in 1 clinical trial for mycosis fungoides, of which 1 is open and 0 are closed. Of the trial that contains CD79B status and mycosis fungoides as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

CD79B is altered in 0.79% of cervical carcinoma patients [3].

CD79B is an inclusion criterion in 1 clinical trial for cervical carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CD79B status and cervical carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

CD79B is altered in 1.12% of cancer patients [3].

CD79B is an inclusion criterion in 1 clinical trial for cancer, of which 1 is open and 0 are closed. Of the trial that contains CD79B status and cancer as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

CD79B is altered in 0.4% of head and neck squamous cell carcinoma patients [3].

CD79B is an inclusion criterion in 1 clinical trial for head and neck squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CD79B status and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

CD79B is an inclusion criterion in 1 clinical trial for adult T-cell acute lymphoblastic leukemia, of which 1 is open and 0 are closed. Of the trial that contains CD79B status and adult T-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

CD79B is an inclusion criterion in 1 clinical trial for anaplastic large cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains CD79B status and anaplastic large cell lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

CD79B is an inclusion criterion in 1 clinical trial for angioimmunoblastic T-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains CD79B status and angioimmunoblastic T-cell lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

CD79B is an inclusion criterion in 1 clinical trial for enteropathy-associated T-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains CD79B status and enteropathy-associated T-cell lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

CD79B is an inclusion criterion in 1 clinical trial for follicular T-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains CD79B status and follicular T-cell lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

CD79B is an inclusion criterion in 1 clinical trial for hepatosplenic T-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains CD79B status and hepatosplenic T-cell lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

CD79B is an inclusion criterion in 1 clinical trial for monomorphic epitheliotropic intestinal T-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains CD79B status and monomorphic epitheliotropic intestinal T-cell lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

CD79B is an inclusion criterion in 1 clinical trial for nasal type extranodal NK/T-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains CD79B status and nasal type extranodal NK/T-cell lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

CD79B is an inclusion criterion in 1 clinical trial for nodal peripheral T-cell lymphoma with TFH phenotype, of which 1 is open and 0 are closed. Of the trial that contains CD79B status and nodal peripheral T-cell lymphoma with TFH phenotype as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

CD79B is an inclusion criterion in 1 clinical trial for peripheral T-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains CD79B status and peripheral T-cell lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

CD79B is an inclusion criterion in 1 clinical trial for peripheral T-cell lymphoma, not otherwise specified, of which 1 is open and 0 are closed. Of the trial that contains CD79B status and peripheral T-cell lymphoma, not otherwise specified as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

CD79B is an inclusion criterion in 1 clinical trial for primary cutaneous T-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains CD79B status and primary cutaneous T-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

CD79B is an inclusion criterion in 1 clinical trial for sezary syndrome, of which 1 is open and 0 are closed. Of the trial that contains CD79B status and sezary syndrome as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

CD79B is an inclusion criterion in 1 clinical trial for subcutaneous panniculitis-like T-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains CD79B status and subcutaneous panniculitis-like T-cell lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].